Possible mechanism of immunosuppression by gramicidin S of S antigen-induced experimental autoimmune uveoretinitis.
Gramicidin S (GrS) suppressed the onset of experimental autoimmune uveoretinitis (EAU) induced with S-antigen in rats, and the proliferation of mitogen-stimulated lymphocytes in culture. As an immunosuppressive mechanism of the cyclic peptide antibiotic we first postulated that the drug exerts its effect as an ionophore. Although all ionophore compounds tested suppressed lymphocyte proliferation, no correlation was observed between changes in intracellular concentrations of Na+ and K+ and the degree of immunosuppression. For example, monensin inhibited lymphocyte proliferation without affecting intracellular Na+ and K+ levels. Thus it was likely that the immunosuppressive effects of the ionophore compounds including GrS were due to their ability to modify cell membrane properties rather than their ionophore activity. We then tested the hypothesis that GrS inhibits transport of metabolic intermediates or metabolites (thymidine and methionine) into lymphocytes. The idea was experimentally supported. Further, inhibition of metabolite transport by GrS was found to be reversible. To investigate whether inhibition of metabolite uptake can be a mechanism of immunosuppression of EAU, endogenously stimulated lymphocytes were isolated from S-antigen-immunized rats at different stages of EAU and the effect of GrS on metabolite uptake by the cells was determined. The activity of lymphocytes to transport metabolites was enhanced at pre-EAU stages and the enhanced metabolite uptake was markedly inhibited by GrS. We interpreted the result to support that inhibition of metabolite uptake by GrS is probably a mechanism of immunosuppression in vivo by this drug.
Matsushima
S
S
Kresge Eye Institute, Department of Ophthalmology, Wayne State University School of Medicine, Detroit, Michigan.
Shichi
H
H
D000818:Animals; D000941:Antigens / Q000037:antagonists & inhibitors; D019393:Arrestin; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001692:Biological Transport / Q000187:drug effects; D002478:Cells, Cultured; D004195:Disease Models, Animal; D005136:Eye Proteins / Q000037:antagonists & inhibitors; D005260:Female; D006096:Gramicidin / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007476:Ionophores / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008715:Methionine / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D051381:Rats; D011917:Rats, Inbred Lew; D012964:Sodium / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism; D015866:Uveitis, Posterior / Q000188:drug therapy*
D000941:Antigens; D019393:Arrestin; D005136:Eye Proteins; D007166:Immunosuppressive Agents; D007476:Ionophores; D006096:Gramicidin; D012964:Sodium; D008715:Methionine; D011188:Potassium; D013936:Thymidine